Logo image of INAB

IN8BIO INC (INAB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INAB - US45674E2081 - Common Stock

1.9058 USD
-0.09 (-4.71%)
Last: 12/26/2025, 10:20:06 AM
Fundamental Rating

1

Overall INAB gets a fundamental rating of 1 out of 10. We evaluated INAB against 530 industry peers in the Biotechnology industry. INAB has a bad profitability rating. Also its financial health evaluation is rather negative. INAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INAB had negative earnings in the past year.
INAB had a negative operating cash flow in the past year.
In the past 5 years INAB always reported negative net income.
INAB had a negative operating cash flow in each of the past 5 years.
INAB Yearly Net Income VS EBIT VS OCF VS FCFINAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of INAB (-123.20%) is worse than 80.75% of its industry peers.
Looking at the Return On Equity, with a value of -156.63%, INAB is doing worse than 65.66% of the companies in the same industry.
Industry RankSector Rank
ROA -123.2%
ROE -156.63%
ROIC N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
INAB Yearly ROA, ROE, ROICINAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

INAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INAB Yearly Profit, Operating, Gross MarginsINAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

INAB has more shares outstanding than it did 1 year ago.
INAB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, INAB has a worse debt to assets ratio.
INAB Yearly Shares OutstandingINAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
INAB Yearly Total Debt VS Total AssetsINAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

INAB has an Altman-Z score of -13.24. This is a bad value and indicates that INAB is not financially healthy and even has some risk of bankruptcy.
INAB has a worse Altman-Z score (-13.24) than 77.92% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that INAB is not too dependend on debt financing.
INAB has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: INAB outperforms 46.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.24
ROIC/WACCN/A
WACCN/A
INAB Yearly LT Debt VS Equity VS FCFINAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

INAB has a Current Ratio of 6.91. This indicates that INAB is financially healthy and has no problem in meeting its short term obligations.
INAB's Current ratio of 6.91 is fine compared to the rest of the industry. INAB outperforms 69.43% of its industry peers.
A Quick Ratio of 6.91 indicates that INAB has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.91, INAB is doing good in the industry, outperforming 69.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.91
Quick Ratio 6.91
INAB Yearly Current Assets VS Current LiabilitesINAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.04% over the past year.
EPS 1Y (TTM)76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.16% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.03%
EPS Next 2Y37.01%
EPS Next 3Y22.88%
EPS Next 5Y21.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INAB Yearly Revenue VS EstimatesINAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
INAB Yearly EPS VS EstimatesINAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INAB. In the last year negative earnings were reported.
Also next year INAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INAB Price Earnings VS Forward Price EarningsINAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INAB Per share dataINAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

INAB's earnings are expected to grow with 22.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.01%
EPS Next 3Y22.88%

More info and screens

0

5. Dividend

5.1 Amount

INAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IN8BIO INC

NASDAQ:INAB (12/26/2025, 10:20:06 AM)

1.9058

-0.09 (-4.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners21.15%
Inst Owner Change-87.7%
Ins Owners3.12%
Ins Owner Change0%
Market Cap8.82M
Revenue(TTM)N/A
Net Income(TTM)-20.66M
Analysts82
Price TargetN/A
Short Float %0.49%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.36%
Min EPS beat(2)32.25%
Max EPS beat(2)32.46%
EPS beat(4)3
Avg EPS beat(4)27.37%
Min EPS beat(4)-2.94%
Max EPS beat(4)47.71%
EPS beat(8)4
Avg EPS beat(8)7.74%
EPS beat(12)7
Avg EPS beat(12)5.45%
EPS beat(16)9
Avg EPS beat(16)2.97%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.13%
EPS NQ rev (1m)7.25%
EPS NQ rev (3m)7.25%
EPS NY rev (1m)-1.52%
EPS NY rev (3m)23.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-5.39
EYN/A
EPS(NY)-2.14
Fwd EYN/A
FCF(TTM)-3.16
FCFYN/A
OCF(TTM)-3.15
OCFYN/A
SpS0
BVpS2.85
TBVpS2.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -123.2%
ROE -156.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.56%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.91
Quick Ratio 6.91
Altman-Z -13.24
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)217.04%
Cap/Depr(5y)140.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.11%
EPS Next Y70.03%
EPS Next 2Y37.01%
EPS Next 3Y22.88%
EPS Next 5Y21.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.28%
EBIT Next 3Y-17.46%
EBIT Next 5Y-5.55%
FCF growth 1Y48.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.78%
OCF growth 3YN/A
OCF growth 5YN/A

IN8BIO INC / INAB FAQ

What is the ChartMill fundamental rating of IN8BIO INC (INAB) stock?

ChartMill assigns a fundamental rating of 1 / 10 to INAB.


What is the valuation status of IN8BIO INC (INAB) stock?

ChartMill assigns a valuation rating of 1 / 10 to IN8BIO INC (INAB). This can be considered as Overvalued.


What is the profitability of INAB stock?

IN8BIO INC (INAB) has a profitability rating of 0 / 10.


How financially healthy is IN8BIO INC?

The financial health rating of IN8BIO INC (INAB) is 3 / 10.